Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Crizanlizumab Clear all

Conditions: Sickle Cell Disease (SCD)
Interventions: Crizanlizumab (SEG101), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Charlotte, North Carolina + 2 more

Conditions: Covid19
Interventions: theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor; Drug
Lead sponsor: Matthew Neal MD; Other
Eligibility: 18 Years and older
Enrollment: 3,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 81
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more

Conditions: Sickle Cell Disease
Interventions: Crizanlizumab, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 17
States / cities: Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 13 more

Conditions: RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Interventions: Crizanlizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 25 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years and older
Enrollment: 297 participants
Timeline: 2021 – 2022
U.S. locations: 11
States / cities: Birmingham, Alabama • Wilmington, Delaware • St. Petersburg, Florida + 8 more

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 16 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Sickle Cell Disease (SCD)
Interventions: crizanlizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 12
States / cities: Orange, Florida • Tampa, Florida • Atlanta, Georgia + 9 more

Conditions: Sickle Cell Disease
Interventions: Crizanlizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Months to 100 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 7
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Augusta, Georgia + 3 more

Conditions: Sickle Cell Disease
Interventions: Crizanlizumab; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years to 99 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Priapism
Interventions: Crizanlizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Farmington, Connecticut • Washington D.C., District of Columbia + 10 more

Conditions: COVID-19
Interventions: Crizanlizumab, 0.9% saline; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sickle Cell Disease (SCD)
Interventions: Crizanlizuamb, Standard of Care; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: Birmingham, Alabama • Chicago, Illinois • Baton Rouge, Louisiana + 3 more

Conditions: Sickle Cell Disease (SCD)
Interventions: Crizanlizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 9 more

Conditions: Sickle Cell Disease
Interventions: Crizanlizumab; Other
Lead sponsor: Andria Ford; Other
Eligibility: 16 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Characteristics of Patients With Sickle Cell Disease

A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

Crizanlizumab for Treating COVID-19 Vasculopathy

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA